Duchenne Muscular Dystrophy (DMD) Pipeline Analysis 2018 - Focusing On Clinical Trials And Results, Drug Profiling, Patents, Collaborations, And Other Developments

1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
• Drug Name
• Generic Name
• Synonyms
• Company
• Collaborator
• Route of administration
• Target 
• Mechanism of Action
• Technology
• Molecule type
• CAS Number
• Weight
• Chemical Formula
• IUPAC name
• ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company profiling
6.1. Santhera Pharmaceuticals
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. PTC Therapeutics
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.3. Nippon Shinyaku Co., Ltd.
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.4. ReveraGen BioPharma, Inc.
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.5. Sarepta Therapeutics, Inc.
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.6. Italfarmaco S.p.A.
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.7. BioMarin
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.8. FibroGen, Inc.
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.9. RSPR Pharma AB
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.10. F. Hoffmann-La Roche Ltd.

6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT
6.11. Summit Therapeutics plc
6.11.1. Introduction
6.11.2. Financials
6.11.3. Products and Services
6.11.4. SWOT 
6.12. Pfizer Inc.
6.12.1. Introduction
6.12.2. Financials
6.12.3. Products and Services
6.12.4. SWOT
6.13. Daiichi Sankyo Company, Limited 
6.13.1. Introduction
6.13.2. Financials
6.13.3. Products and Services
6.13.4. SWOT
6.14. Akashi Therapeutics
6.14.1. Introduction
6.14.2. Financials
6.14.3. Products and Services
6.14.4. SWOT
6.15. Beike Biotechnology Co., Ltd.
6.15.1. Introduction
6.15.2. Financials
6.15.3. Products and Services
6.15.4. SWOT
6.16. Cumberland Pharmaceuticals Inc.
6.16.1. Introduction
6.16.2. Financials
6.16.3. Products and Services
6.16.4. SWOT
6.17. Solid Biosciences
6.17.1. Introduction
6.17.2. Financials
6.17.3. Products and Services
6.17.4. SWOT
6.18. Taiho Pharmaceutical Co., Ltd.
6.18.1. Introduction
6.18.2. Financials
6.18.3. Products and Services
6.18.4. SWOT
6.19. Syneos Health
6.19.1. Introduction

---

Santhera Pharmaceuticals
PTC Therapeutics
Nippon Shinyaku Co., Ltd.
ReveraGen BioPharma, Inc.
Sarepta Therapeutics, Inc.
Italfarmaco S.p.A.
BioMarin
FibroGen, Inc.
RSPR Pharma AB
F. Hoffmann-La Roche Ltd.
Summit Therapeutics plc
Pfizer Inc.
Daiichi Sankyo Company, Limited 
Akashi Therapeutics
Beike Biotechnology Co., Ltd.
Cumberland Pharmaceuticals Inc.
Solid Biosciences
Taiho Pharmaceutical Co., Ltd.
Syneos Health

---